Literature DB >> 7641363

Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.

M Azizi1, G Chatellier, T T Guyene, D Murieta-Geoffroy, J Ménard.   

Abstract

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors do not decrease plasma angiotensin (Ang) II levels 24 hours after drug intake to the same extent as at peak. This intermittent partial "escape" is explained either by a renin-mediated reactive rise in plasma Ang I or by non-ACE-dependent Ang II generation. We therefore tested the hypothesis that a combination of ACE inhibition and Ang II blockade may have additive biological and hemodynamic effects. METHODS AND
RESULTS: In a single-dose, double-blind, randomized, four-way, crossover study, an Ang II antagonist (losartan 50 mg), an ACE inhibitor (captopril 50 mg), their combination, and matched placebos were orally administered to 12 normotensive male volunteers maintained in mild sodium depletion. When captopril 50 mg and losartan 50 mg were given alone, the magnitude of their effects on blood pressure, plasma active renin, Ang I, and aldosterone was similar, whereas the kinetics of their effects were different, reflecting differences in drug pharmacokinetics. The losartan-captopril combination completely suppressed the rise in plasma Ang II induced by losartan 2 hours after drug intake (3.3 +/- 3.6 pg/mL versus 20.3 +/- 19.1 pg/mL, respectively, P < .05). Six hours after drug intake, the losartan-captopril combination induced a significantly greater decrease in mean blood pressure than that produced by either losartan or captopril alone (73 +/- 7 mm Hg versus 79 +/- 8 mm Hg versus 81 +/- 7 mm Hg, respectively, P < .05). The maximum placebo-subtracted falls in mean blood pressure for the losartan-captopril combination, captopril 50 mg, and losartan 50 mg were 14 +/- 5 mm Hg, 10 +/- 3 mm Hg, and 9 +/- 6 mm Hg, respectively (F2.22 = 3.45, P < .05). The duration of the mean blood pressure fall was not prolonged by the combination. After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05). The combination had no additive effects on plasma aldosterone decrease when compared with either losartan or captopril alone (58 +/- 17% versus 51 +/- 20% versus 53 +/- 21%, respectively, NS).
CONCLUSIONS: The combined administration of a standard single oral dose of an ACE inhibitor and an Ang II antagonist to mildly sodium-depleted normal subjects (1) had a major additive effect on plasma renin rise, (2) induced an additional mean blood pressure reduction, and (3) had no additive effect on plasma aldosterone fall.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641363     DOI: 10.1161/01.cir.92.4.825

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  37 in total

Review 1.  Clinical case studies in heart failure management.

Authors:  R J MacFadyen; P Shiels; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

2.  Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.

Authors:  R Weidenbach; R Schulz; P Gres; M Behrends; H Post; G Heusch
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 3.  Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.

Authors:  Niels Holmark Andersen; Carl Erik Mogensen
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

4.  Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents.

Authors:  Chih-Chang Wei; Naoki Hase; Yukiko Inoue; Eddie W Bradley; Eiji Yahiro; Ming Li; Nawazish Naqvi; Pamela C Powell; Ke Shi; Yoshimasa Takahashi; Keijiro Saku; Hidenori Urata; Louis J Dell'italia; Ahsan Husain
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

Review 5.  The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors--what has time told us?

Authors:  Mary Rose Fabi; John R Teerlink
Journal:  Curr Heart Fail Rep       Date:  2005-08

6.  Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli.

Authors:  Michel Azizi; Xavier Iturrioz; Anne Blanchard; Séverine Peyrard; Nadia De Mota; Nicolas Chartrel; Hubert Vaudry; Pierre Corvol; Catherine Llorens-Cortes
Journal:  J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 10.121

7.  Aliskiren combined with losartan: Thor's hammer or Sigurd's sword?

Authors:  Thomas R Lux; Heinrich Taegtmeyer
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 8.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

9.  Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension.

Authors:  J D Bisognano; L D Horwitz
Journal:  West J Med       Date:  1998-04

10.  ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.

Authors:  Timothy Kwok; Jason Leung; Elizabeth Barrett-Connor
Journal:  Age Ageing       Date:  2017-01-10       Impact factor: 10.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.